Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets

Muthuvel Jayachandran, Antonio Sanzo, Whyte G. Owen, Virginia M Miller

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Oral estrogen treatment increases thrombotic risk. Tissue factor (TF), tissue factor pathway inhibitor (TFPI), and platelet interaction with leukocytes are important determinants of thrombogenesis. Therefore, the present study was designed to define and compare platelet TF and TFPI mRNA and adhesion protein expression in platelets derived from animals treated with different types of oral estrogens. Ovariectomized pigs were treated with 17β-estradiol (2 mg/day), conjugated equine estrogen (CEE; 0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Compared with intact animals, ovariectomy and treatment differentially affected populations of leukocytes: neutrophils decreased whereas lymphocytes increased significantly 4 wk after ovariectomy and with 17β-estradiol and CEE treatments; eosinophils increased only with 17β-estradiol treatment. Content of TF protein increased in platelets from 17β-estradiol- and raloxifene-treated pigs, whereas TF mRNA was detected only in platelets from 17β-estradiol- and CEE treated pigs. TFPI mRNA increased in platelets after ovariectomy and estrogen treatment. Only a trace of TFPI protein was detected, but a higher-molecular-mass protein was observed in all treatment groups. Expression of CD40 and CD40 ligand increased with ovariectomy and decreased with 17β-estradiol and CEE treatments more than with raloxifene. The ratio of activated to basal P-selectin expression decreased with ovariectomy and increased with raloxifene treatments. These results suggest that estrogenic formulations may affect individual thrombotic risk by different mechanisms that regulate TF and platelet-leukocytic interactions. These studies provide the rationale for evaluation of interactions among platelets and TF and TFPI expression on thrombin generation during estrogen treatment in humans.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume289
Issue number5 58-5
DOIs
StatePublished - Nov 2005

Fingerprint

Thromboplastin
Blood Platelets
Ovariectomy
Estradiol
Estrogens
Swine
Messenger RNA
Proteins
Leukocytes
Conjugated (USP) Estrogens
CD40 Ligand
P-Selectin
lipoprotein-associated coagulation inhibitor
Eosinophils
Thrombin
Neutrophils
Lymphocytes
Raloxifene Hydrochloride
Population

Keywords

  • 17β-estradiol
  • CD40
  • Conjugated equine estrogen
  • Leukocytes
  • Raloxifene

ASJC Scopus subject areas

  • Physiology

Cite this

Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. / Jayachandran, Muthuvel; Sanzo, Antonio; Owen, Whyte G.; Miller, Virginia M.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 289, No. 5 58-5, 11.2005.

Research output: Contribution to journalArticle

@article{3a68a211852f45e3a8ba949d7ba0f30c,
title = "Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets",
abstract = "Oral estrogen treatment increases thrombotic risk. Tissue factor (TF), tissue factor pathway inhibitor (TFPI), and platelet interaction with leukocytes are important determinants of thrombogenesis. Therefore, the present study was designed to define and compare platelet TF and TFPI mRNA and adhesion protein expression in platelets derived from animals treated with different types of oral estrogens. Ovariectomized pigs were treated with 17β-estradiol (2 mg/day), conjugated equine estrogen (CEE; 0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Compared with intact animals, ovariectomy and treatment differentially affected populations of leukocytes: neutrophils decreased whereas lymphocytes increased significantly 4 wk after ovariectomy and with 17β-estradiol and CEE treatments; eosinophils increased only with 17β-estradiol treatment. Content of TF protein increased in platelets from 17β-estradiol- and raloxifene-treated pigs, whereas TF mRNA was detected only in platelets from 17β-estradiol- and CEE treated pigs. TFPI mRNA increased in platelets after ovariectomy and estrogen treatment. Only a trace of TFPI protein was detected, but a higher-molecular-mass protein was observed in all treatment groups. Expression of CD40 and CD40 ligand increased with ovariectomy and decreased with 17β-estradiol and CEE treatments more than with raloxifene. The ratio of activated to basal P-selectin expression decreased with ovariectomy and increased with raloxifene treatments. These results suggest that estrogenic formulations may affect individual thrombotic risk by different mechanisms that regulate TF and platelet-leukocytic interactions. These studies provide the rationale for evaluation of interactions among platelets and TF and TFPI expression on thrombin generation during estrogen treatment in humans.",
keywords = "17β-estradiol, CD40, Conjugated equine estrogen, Leukocytes, Raloxifene",
author = "Muthuvel Jayachandran and Antonio Sanzo and Owen, {Whyte G.} and Miller, {Virginia M}",
year = "2005",
month = "11",
doi = "10.1152/ajpheart.01292.2004",
language = "English (US)",
volume = "289",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5 58-5",

}

TY - JOUR

T1 - Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets

AU - Jayachandran, Muthuvel

AU - Sanzo, Antonio

AU - Owen, Whyte G.

AU - Miller, Virginia M

PY - 2005/11

Y1 - 2005/11

N2 - Oral estrogen treatment increases thrombotic risk. Tissue factor (TF), tissue factor pathway inhibitor (TFPI), and platelet interaction with leukocytes are important determinants of thrombogenesis. Therefore, the present study was designed to define and compare platelet TF and TFPI mRNA and adhesion protein expression in platelets derived from animals treated with different types of oral estrogens. Ovariectomized pigs were treated with 17β-estradiol (2 mg/day), conjugated equine estrogen (CEE; 0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Compared with intact animals, ovariectomy and treatment differentially affected populations of leukocytes: neutrophils decreased whereas lymphocytes increased significantly 4 wk after ovariectomy and with 17β-estradiol and CEE treatments; eosinophils increased only with 17β-estradiol treatment. Content of TF protein increased in platelets from 17β-estradiol- and raloxifene-treated pigs, whereas TF mRNA was detected only in platelets from 17β-estradiol- and CEE treated pigs. TFPI mRNA increased in platelets after ovariectomy and estrogen treatment. Only a trace of TFPI protein was detected, but a higher-molecular-mass protein was observed in all treatment groups. Expression of CD40 and CD40 ligand increased with ovariectomy and decreased with 17β-estradiol and CEE treatments more than with raloxifene. The ratio of activated to basal P-selectin expression decreased with ovariectomy and increased with raloxifene treatments. These results suggest that estrogenic formulations may affect individual thrombotic risk by different mechanisms that regulate TF and platelet-leukocytic interactions. These studies provide the rationale for evaluation of interactions among platelets and TF and TFPI expression on thrombin generation during estrogen treatment in humans.

AB - Oral estrogen treatment increases thrombotic risk. Tissue factor (TF), tissue factor pathway inhibitor (TFPI), and platelet interaction with leukocytes are important determinants of thrombogenesis. Therefore, the present study was designed to define and compare platelet TF and TFPI mRNA and adhesion protein expression in platelets derived from animals treated with different types of oral estrogens. Ovariectomized pigs were treated with 17β-estradiol (2 mg/day), conjugated equine estrogen (CEE; 0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Compared with intact animals, ovariectomy and treatment differentially affected populations of leukocytes: neutrophils decreased whereas lymphocytes increased significantly 4 wk after ovariectomy and with 17β-estradiol and CEE treatments; eosinophils increased only with 17β-estradiol treatment. Content of TF protein increased in platelets from 17β-estradiol- and raloxifene-treated pigs, whereas TF mRNA was detected only in platelets from 17β-estradiol- and CEE treated pigs. TFPI mRNA increased in platelets after ovariectomy and estrogen treatment. Only a trace of TFPI protein was detected, but a higher-molecular-mass protein was observed in all treatment groups. Expression of CD40 and CD40 ligand increased with ovariectomy and decreased with 17β-estradiol and CEE treatments more than with raloxifene. The ratio of activated to basal P-selectin expression decreased with ovariectomy and increased with raloxifene treatments. These results suggest that estrogenic formulations may affect individual thrombotic risk by different mechanisms that regulate TF and platelet-leukocytic interactions. These studies provide the rationale for evaluation of interactions among platelets and TF and TFPI expression on thrombin generation during estrogen treatment in humans.

KW - 17β-estradiol

KW - CD40

KW - Conjugated equine estrogen

KW - Leukocytes

KW - Raloxifene

UR - http://www.scopus.com/inward/record.url?scp=27144493239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144493239&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.01292.2004

DO - 10.1152/ajpheart.01292.2004

M3 - Article

C2 - 15964915

AN - SCOPUS:27144493239

VL - 289

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5 58-5

ER -